Peptide conjugation: Before or after nanoparticle formation?

Bioconjugate Chemistry

Volumn 25, Issue 11, 2014, Pages 1971-1983

  Valetti, Sabrina ^a,b,c   Mura, Simona ^a,b   Noiray, Magali ^a,b   Arpicco, Silvia ^c   Dosio, Franco ^c   Vergnaud, Juliette ^a,b   Desmaële, Didier ^a,b   Stella, Barbara ^c   Couvreur, Patrick ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIV PARIS SUD   (France)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDES; SURFACE PLASMON RESONANCE;

BIO-CONJUGATION; BIOCONJUGATES; FUNCTIONALIZED; GEMCITABINE; IN-VITRO; MALEIMIDES; MEAN DIAMETER; MICROENVIRONMENTS; NANOFORMULATION; NANOPARTICLE FORMATION;

NANOPARTICLES;

4 (N) TRISNORSQUALENOYLGEMCITABINE NANOPARTICLE; GEMCITABINE; MALEIMIDE; NANOPARTICLE; PEPTIDE; SECRETED FRIZZLED RELATED PROTEIN 4; SQUALENE DERIVATIVE; UNCLASSIFIED DRUG; DEOXYCYTIDINE; DRUG CARRIER; LIGAND; OLIGOPEPTIDE; ONCOPROTEIN; SFRP4 PROTEIN, HUMAN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CANCER THERAPY; CELL VIABILITY; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MICHAEL ADDITION; MICROENVIRONMENT; MOLECULAR STABILITY; NONHUMAN; PANCREATIC CANCER CELL LINE; PHAGE DISPLAY; PHYSICAL PARAMETERS; PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR BINDING; STEROL SYNTHESIS; SURFACE PLASMON RESONANCE; ZETA POTENTIAL; 3T3 CELL LINE; AMINO ACID SEQUENCE; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG DESIGN; METABOLISM; MOUSE; PARTICLE SIZE; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG CARRIERS; DRUG DESIGN; HUMANS; LIGANDS; MICE; NANOPARTICLES; NIH 3T3 CELLS; OLIGOPEPTIDES; PARTICLE SIZE; PROTO-ONCOGENE PROTEINS;

EID: 84913541061     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc5003423     Document Type: Article

References (59)

1. Hanahan, D. and Weinberg, R. A. (2011) Hallmarks of cancer: the next generation Cell 144, 646-674
2. Krause, D. S. and Van Etten, R. A. (2005) Tyrosine kinases as targets for cancer therapy N. Engl. J. Med. 353, 172-187
3. Collins, I. and Workman, P. (2006) New approaches to molecular cancer therapeutics Nat. Chem. Biol. 2, 689-700
4. Chari, R. V. (2008) Targeted cancer therapy: conferring specificity to cytotoxic drugs Acc. Chem. Res. 41, 98-107
5. Dosio, F., Brusa, P., and Cattel, L. (2011) Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components Toxins (Basel) 3, 848-883
6. Flygare, J. A., Pillow, T. H., and Aristoff, P. (2013) Antibody-drug conjugates for the treatment of cancer Chem. Biol. Drug Des. 81, 113-121
7. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm268781.htm.
8. http://www.medscape.com/viewarticle/779751.
9. Wang, M. and Thanou, M. (2010) Targeting nanoparticles to cancer Pharmacol. Res. 62, 90-99
10. Montet, X., Funovics, M., Montet-Abou, K., Weissleder, R., and Josephson, L. (2006) Multivalent effects of RGD peptides obtained by nanoparticle display J. Med. Chem. 49, 6087-6093
11. Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., and Couvreur, P. (2013) Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery Chem. Soc. Rev. 42, 1147-1235
12. Valetti, S., Mura, S., Stella, B., and Couvreur, P. (2013) Rational design for multifunctional non-liposomal lipid-based nanocarriers for cancer management: theory to practice J. Nanobiotechnology 11, S6
13. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., and Langer, R. (2007) Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2, 751-760
14. Davis, M. E., Chen, Z. G., and Shin, D. M. (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer Nat. Rev. Drug Discovery 7, 771-782
15. Cheng, Z., Al Zaki, A., Hui, J. Z., Muzykantov, V. R., and Tsourkas, A. (2012) Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities Science 338, 903-910
16. Lammers, T., Kiessling, F., Hennink, W. E., and Storm, G. (2012) Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress J. Controlled Release 161, 175-187
17. Bae, Y., Nishiyama, N., and Kataoka, K. (2007) In vivo antitumor activity of the folate-conjugated pH-sensitive polymeric micelle selectively releasing adriamycin in the intracellular acidic compartments Bioconjugate Chem. 18, 1131-1139
18. Canovi, M., Markoutsa, E., Lazar, A. N., Pampalakis, G., Clemente, C., Re, F., Sesana, S., Masserini, M., Salmona, M., Duyckaerts, C., Flores, O., Gobbi, M., and Antimisiaris, S. G. (2011) The binding affinity of anti-Abeta1-42 MAb-decorated nanoliposomes to Abeta1-42 peptides in vitro and to amyloid deposits in post-mortem tissue Biomaterials 32, 5489-5497
19. Fakhari, A., Baoum, A., Siahaan, T. J., Le, K. B., and Berkland, C. (2011) Controlling ligand surface density optimizes nanoparticle binding to ICAM-1 J. Pharm. Sci. 100, 1045-1056
20. Huwyler, J., Wu, D., and Pardridge, W. M. (1996) Brain drug delivery of small molecules using immunoliposomes Proc. Natl. Acad. Sci. U. S. A. 93, 14164-14169
21. Le Droumaguet, B., Souguir, H., Brambilla, D., Verpillot, R., Nicolas, J., Taverna, M., Couvreur, P., and Andrieux, K. (2011) Selegiline-functionalized, PEGylated poly(alkyl cyanoacrylate) nanoparticles: Investigation of interaction with amyloid-beta peptide and surface reorganization Int. J. Pharm. 416, 453-460
22. Tassa, C., Duffner, J. L., Lewis, T. A., Weissleder, R., Schreiber, S. L., Koehler, A. N., and Shaw, S. Y. (2010) Binding affinity and kinetic analysis of targeted small molecule-modified nanoparticles Bioconjugate Chem. 21, 14-19
23. Couvreur, P., Stella, B., Reddy, L. H., Hillaireau, H., Dubernet, C., Desmaele, D., Lepetre-Mouelhi, S., Rocco, F., Dereuddre-Bosquet, N., Clayette, P., Rosilio, V., Marsaud, V., Renoir, J. M., and Cattel, L. (2006) Squalenoyl nanomedicines as potential therapeutics Nano Lett. 6, 2544-2548
24. Oberstein, P. E. and Saif, M. W. (2011) First-line treatment for advanced pancreatic cancer. Highlights from the ″2011 ASCO Gastrointestinal Cancers Symposium″. San Francisco, CA, USA. January 20-22, 2011 Journal of Oncology Practice 12, 96-100
25. Reddy, L. H., Renoir, J. M., Marsaud, V., Lepetre-Mouelhi, S., Desmaele, D., and Couvreur, P. (2009) Anticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumor Mol. Pharmaceutics 6, 1526-1535
26. Reddy, L. H., Ferreira, H., Dubernet, C., Mouelhi, S. L., Desmaele, D., Rousseau, B., and Couvreur, P. (2008) Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms Anticancer Drugs 19, 999-1006
27. Rejiba, S., Reddy, L. H., Bigand, C., Parmentier, C., Couvreur, P., and Hajri, A. (2011) Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer Nanomedicine 7, 841-849
28. Hidalgo, M. (2010) Pancreatic cancer N. Engl. J. Med. 362, 1605-1617
29. Joyce, J. A., Laakkonen, P., Bernasconi, M., Bergers, G., Ruoslahti, E., and Hanahan, D. (2003) Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis Cancer Cell. 4, 393-403
30. Valetti, S., Maione, F., Mura, S., Stella, B., Desmaele, D., Noiray, M., Vergnaud, J., Vauthier, C., Cattel, L., Giraudo, E., and Couvreur, P. (2014) Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor J. Controlled Release 192C, 29-39
31. Raouane, M., Desmaele, D., Gilbert-Sirieix, M., Gueutin, C., Zouhiri, F., Bourgaux, C., Lepeltier, E., Gref, R., Ben Salah, R., Clayman, G., Massaad-Massade, L., and Couvreur, P. (2011) Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma J. Med. Chem. 54, 4067-4076
32. Bekkara-Aounallah, F., Gref, R., Othman, M., Reddy, L. H., Pili, B., Allain, V., Bourgaux, C., Hillaireau, H., Lepêtre-Mouelhi, S., Desmaële, D., Nicolas, J., Chafi, N., and Couvreur, P. (2008) Novel PEGylated nanoassemblies made of self-assembled squalenoyl nucleoside analogues Adv. Funct. Mater. 18, 3715-3725
33. Desmaele, D., Gref, R., and Couvreur, P. (2012) Squalenoylation: a generic platform for nanoparticular drug delivery J. Controlled Release 161, 609-618
34. Lepeltier, E., Bourgaux, C., Rosilio, V., Poupaert, J. H., Meneau, F., Zouhiri, F., Lepetre-Mouelhi, S., Desmaele, D., and Couvreur, P. (2013) Self-assembly of squalene-based nucleolipids: relating the chemical structure of the bioconjugates to the architecture of the nanoparticles Langmuir 29, 14795-14803
35. Bouchemal, K., Briancon, S., Perrier, E., and Fessi, H. (2004) Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimization Int. J. Pharm. 280, 241-251
36. Ganachaud, F. and Katz, J. L. (2005) Nanoparticles and nanocapsules created using the Ouzo effect: Spontaneous emulsification as an alternative to ultrasonic and high-shear devices ChemPhysChem 6, 209-216
37. Legrand, P., Lesieur, S., Bochot, A., Gref, R., Raatjes, W., Barratt, G., and Vauthier, C. (2007) Influence of polymer behaviour in organic solution on the production of polylactide nanoparticles by nanoprecipitation Int. J. Pharm. 344, 33-43
38. Yu, W., Doegito, E. S. T., Barratt, G., Fessi, H., Devissaguet, J. P., and Puisieux, F. (1993) A novel approach to the preparation of injectable emulsions by a spontaneous emulsification process Int. J. Pharm. 89, 139-146
39. Agostoni, V., Chalati, T., Horcajada, P., Willaime, H., Anand, R., Semiramoth, N., Baati, T., Hall, S., Maurin, G., Chacun, H., Bouchemal, K., Martineau, C., Taulelle, F., Couvreur, P., Rogez-Kreuz, C., Clayette, P., Monti, S., Serre, C., and Gref, R. (2013) Towards an improved anti-HIV activity of NRTI via metal-organic frameworks nanoparticles Adv. Healthc. Mater. 2, 1630-1637
40. Bouchemal, K. (2008) New challenges for pharmaceutical formulations and drug delivery systems characterization using isothermal titration calorimetry Drug Discovery Today 13, 960-972
41. Mazzaferro, S., Bouchemal, K., Gallard, J. F., Iorga, B. I., Cheron, M., Gueutin, C., Steinmesse, C., and Ponchel, G. (2011) Bivalent sequential binding of docetaxel to methyl-beta-cyclodextrin Int. J. Pharm. 416, 171-180
42. Hermanson, G. T. (1996) Bioconjugate Techniques, 1 st ed., Academic Press, San Diego.
43. Furgeson, D. Y., Dreher, M. R., and Chilkoti, A. (2006) Structural optimization of a ″smart″ doxorubicin-polypeptide conjugate for thermally targeted delivery to solid tumors J. Controlled Release 110, 362-369
44. Avvakumova, S., Colombo, M., Tortora, P., and Prosperi, D. (2014) Biotechnological approaches toward nanoparticle biofunctionalization Trends Biotechnol. 32, 11-20
45. Occhipinti, E., Verderio, P., Natalello, A., Galbiati, E., Colombo, M., Mazzucchelli, S., Salvade, A., Tortora, P., Doglia, S. M., and Prosperi, D. (2011) Investigating the structural biofunctionality of antibodies conjugated to magnetic nanoparticles Nanoscale 3, 387-390
46. Wawrzak, D., Metioui, M., Willems, E., Hendrickx, M., de Genst, E., and Leyns, L. (2007) Wnt3a binds to several sFRPs in the nanomolar range Biochem. Biophys. Res. Commun. 357, 1119-1123
47. Cedervall, T., Lynch, I., Lindman, S., Berggard, T., Thulin, E., Nilsson, H., Dawson, K. A., and Linse, S. (2007) Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles Proc. Natl. Acad. Sci. U.S.A. 104, 2050-2055
48. Lundqvist, M., Stigler, J., Elia, G., Lynch, I., Cedervall, T., and Dawson, K. A. (2008) Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts Proc. Natl. Acad. Sci. U.S.A 105, 14265-14270
49. Blanchette, C. D., Fischer, N. O., Corzett, M., Bench, G., and Hoeprich, P. D. (2010) Kinetic analysis of His-tagged protein binding to nickel-chelating nanolipoprotein particles Bioconjugate Chem. 21, 1321-1330
50. Mourtas, S., Canovi, M., Zona, C., Aurilia, D., Niarakis, A., La Ferla, B., Salmona, M., Nicotra, F., Gobbi, M., and Antimisiaris, S. G. (2011) Curcumin-decorated nanoliposomes with very high affinity for amyloid-beta1-42 peptide Biomaterials 32, 1635-1645
51. Choi, C. H., Alabi, C. A., Webster, P., and Davis, M. E. (2010) Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles Proc. Natl. Acad. Sci. U.S.A. 107, 1235-1240
52. Hillaireau, H. and Couvreur, P. (2009) Nanocarriers' entry into the cell: relevance to drug delivery Cell. Mol. Life Sci. 66, 2873-2896
53. Wang, Y. C., Lee, Y. H., Huang, G. C., Lin, Y. H., Fan-Chiang, M. H., Chiu, A. W., and Huang, Y. L. (2006) Enhanced transformation and chemosensitivity of NIH3T3 cells transduced with hepatoma up-regulated protein Biochem. Biophys. Res. Commun. 340, 244-249
54. Keyes, K., Cox, K., Treadway, P., Mann, L., Shih, C., Faul, M. M., and Teicher, B. A. (2002) An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy Cancer Res. 62, 5597-5602
55. Fessi, H., Puisieux, F., Devissaguet, J. P., Ammoury, N., and Benita, S. (1989) Nanocapsule formation by interfacial polymer deposition following solvent displacement Int. J. Pharm. 55, R1-R4
56. Ellman, G. L. (1958) A colorimetric method for determining low concentrations of mercaptans Arch. Biochem. Biophys. 74, 443-450
57. Othman, M., Bouchemal, K., Couvreur, P., and Gref, R. (2009) Microcalorimetric investigation on the formation of supramolecular nanoassemblies of associative polymers loaded with gadolinium chelate derivatives Int. J. Pharm. 379, 218-225
58. Segura-Sanchez, F., Bouchemal, K., Lebas, G., Vauthier, C., Santos-Magalhaes, N. S., and Ponchel, G. (2009) Elucidation of the complexation mechanism between (+)-usnic acid and cyclodextrins studied by isothermal titration calorimetry and phase-solubility diagram experiments J. Mol. Recognit. 22, 232-241
59. Uhlen, M., Oksvold, P., Fagerberg, L., Lundberg, E., Jonasson, K., Forsberg, M., Zwahlen, M., Kampf, C., Wester, K., Hober, S., Wernerus, H., Bjorling, L., and Ponten, F. (2010) Towards a knowledge-based Human Protein Atlas Nat. Biotechnol. 28, 1248-1250